Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044460
Status:
COMPLETED
Last Update Posted:
2017-10-09
First Post:
2002-08-29
Brief Title:
Efficacy and Safety In Poorly Controlled Type 2 Diabetics
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A 24-week Randomized Double-Blind Parallel-Group Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens 4mg OD and 8mg OD in Poorly-Controlled Drug Naive Patients With Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to gain safety and efficacy information in patients with type 2 diabetes who have not previously taken any oral antidiabetic medications and who have an HbA1c value of greater than or equal to 10 despite diet and exercise
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None